Plant-Derived and Endogenous Cannabinoids in Epilepsy
- 577 Downloads
Cannabis is one of the oldest psychotropic drugs and its anticonvulsant properties have been known since the last century. The aim of this reveiw was to analyze the efficacy of cannabis in the treatment of epilepsy in adults and children. In addition, a description of the involvement of the endocannabinoid system in epilepsy is given in order to provide a biochemical background to the effects of endogenous cannabinoids in our body. General tolerability and adverse events associated with cannabis treatment are also investigated. Several anecdotal reports and clinical trials suggest that in the human population cannabis has anticonvulsant properties and could be effective in treating partial epilepsies and generalized tonic-clonic seizures, still known as “grand mal.” They are based, among other factors, on the observation that in individuals who smoke marijuana to treat epilepsy, cessation of cannabis use precipitates the re-emergence of convulsive seizures, whereas resuming consumption of this psychotropic drug controls epilepsy in a reproducible manner. In conclusion, there is some anecdotal evidence for the potential efficacy of cannabis in treating epilepsy. Though there has been an increased effort by patients with epilepsy, their caregivers, growers, and legislators to legalize various forms of cannabis, there is still concern about its efficacy, relative potency, availability of medication-grade preparations, dosing, and potential short- and long-term side effects, including those on prenatal and childhood development.
KeywordsFatty Acid Amide Hydrolase Anticonvulsant Property Medical Marijuana Dravet Syndrome Expanded Access Program
Compliance with Ethical Standards
The authors have no financial relationships to disclose with regard to this article.
Conflict of interest
AV, MC, MM and FF have no conflicts of interest.
- 1.Ben Amar M, L´eonard L. Chapter 16: Cannabis. In: L´eonard L, Ben Amar M, editors. Les Psychotropes: Pharmacologie et Toxicomanie. Montreal: Les Presses de l’Universit´e de Montr´eal; 2002. p. 571–627.Google Scholar
- 2.O’Shaugnessy WB. On the preparations of the Indian hemp, or gunjah (Cannabis indica): their effects on the animal system in health, and their utility in the treatment of tetanus and other convulsive diseases. Transactions of Medical and Physical Society of Bengal, 1838–1840. p. 421–461.Google Scholar
- 4.Carter GT, Weijdt P, Kyashna-Tocha M, Abrams DI. Medicinal cannabis: rational guidelines for dosing. Drugs. 2004;75:464–70.Google Scholar
- 5.Fankhauser M. Chapter 4: history of cannabis in Western medicine. In: Grotenhermen F, Russo R, editors. Cannabis and CBss: pharmacology, toxicology and therapeutic potential. New York: The Haworth Integrative Healing Press; 2002. p. 37–51.Google Scholar
- 6.Ben Amar M. Cannabinoids in medicine: a review of their therapeutic potential. J Ethnopharmacol. 2006;105:1–25.Google Scholar
- 8.Hoey J. Marijuana: federal smoke clears a little. CMAJ. 2001;164:1397.Google Scholar
- 9.Health Canada. Medical Use of Marihuana. Stakeholder Statistics. Ottawa: Office of Cannabis Medical Access, Health Canada; 2005. p. 2.Google Scholar
- 11.Health Canada CIHR. Medical Marihuana Research Program. Ottawa: Health Canada and Canadian Institutes of Health Research; 1999. p. 7.Google Scholar
- 12.Health Canada [website]. Medical use of marijuana. Ottawa: Health Canada; 2015. Available from: http://www.hc-sc.gc.ca/dhp-mps/marihuana/index-eng.php. Accessed 10 July 2015.
- 13.Collège des médecins du Québec. Guidelines concerning the prescription of dried cannabis for medical purposes. Montreal: Collège des médecins du Québec; 2014. Available from: http://www.cmq.org/en/MedecinsMembres/DossierMembreFormulaires/~/media/Files/Cannabis/Guidelinesprescription-cannabis.pdf?111402. Accessed 10 July 2015.
- 15.McKim WA. Drugs and behavior. An introduction to behavioral pharmacology, 4th ed. Upper Saddle River: Prentice-Hall; 2000. p. 400.Google Scholar
- 16.Pertwee RG, Howlett AC, Abood ME, Alexander SP, Di Marzo V, Elphick MR, Greasley PJ, Hansen HS, Kunos G, Mackie K, Mechoulam R, Ross RA. International Union of Basic and Clinical Pharmacology. LXXIX. Cannabinoid receptors and their ligands: beyond CB1 and CB2. Pharmacol Rev. 2010;62:588–631.CrossRefPubMedPubMedCentralGoogle Scholar
- 21.Sánchez C, de Ceballos ML, Gomez del Pulgar T, Rueda D, Corbacho C, Velasco G, Galve-Roperh I, Huffman JW, Ramón y Cajal S, Guzmán M. Inhibition of glioma growth in vivo by selective activation of the CB(2) cannabinoid receptor. Cancer Res. 2001;61:5784–89.Google Scholar
- 30.Tsuboi K, Sun YX, Okamoto Y, Araki N, Tonai T, Ueda N. Molecular characterization of N-acylethanolamine-hydrolyzing acid amidase, a novel member of the choloylglycine hydrolase family with structural and functional similarity to acid ceramidase. J Biol Chem. 2005;280:11082–92.CrossRefPubMedGoogle Scholar
- 31.Bisogno T, Howell F, Williams G, Minassi A, Cascio MG, Ligresti A, Matias I, Schiano-Moriello A, Paul P, Williams EJ, Gangadharan U, Hobbs C, Di Marzo V, Doherty P. Cloning of the first sn1-DAG lipases points to the spatial and temporal regulation of endocannabinoid signaling in the brain. J Cell Biol. 2003;163:463–8.CrossRefPubMedPubMedCentralGoogle Scholar
- 37.Romigi A, Bari M, Placidi F, Marciani MG, Malaponti M, Torelli F, Izzi F, Prosperetti C, Zannino S, Corte F, Chiaramonte C, Maccarrone M. Cerebrospinal fluid levels of the endocannabinoid anandamide are reduced in patients with untreated newly diagnosed temporal lobe epilepsy. Epilepsia. 2010;51:768–72.CrossRefPubMedGoogle Scholar
- 45.Carletti F, Gambino G, Rizzo V, Ferraro G, Sardo P. Cannabinoid and nitric oxide signaling interplay in the modulation of hippocampal hyperexcitability: study on electrophysiological and behavioral models of temporal lobe epilepsy in the rat. Neuroscience. 2015;303:149–59.CrossRefPubMedGoogle Scholar
- 47.Karanian DA, Karim SL, Wood JT, Williams JS, Lin S, Makriyannis A, Bahr BA. Endocannabinoid enhancement protects against kainic acid-induced seizures and associated brain damage. J Pharmacol Exp Ther. 2007;322:1059–66.Google Scholar
- 48.Marsicano G, Goodenough S, Monory K, Hermann H, Eder M, Cannich A, Azad SC, Cascio MG, Gutiérrez SO, van der Stelt M, López-Rodriguez ML, Casanova E, Schütz G, Zieglgänsberger W, Di Marzo V, Behl C. Lutz B CB1 cannabinoid receptors and on-demand defense against excitotoxicity. Science. 2003;302:84–8.CrossRefPubMedGoogle Scholar
- 49.Naidoo V, Karanian DA, Vadivel SK, Locklear JR, Wood JT, Nasr M, Quizon PM, Graves EE, Shukla V, Makriyannis A, Bahr BA. Equipotent inhibition of fatty acid amide hydrolase and monoacylglycerol lipase—dual targets of the endocannabinoid system to protect against seizure pathology. Neurotherapeutics. 2012;9:801–13.CrossRefPubMedPubMedCentralGoogle Scholar
- 50.Mechoulam R. Chapter 1: the pharmacohistory of Cannabis sativa. In: Mechoulan R, editor. CBss as therapeutic agents. Boca Raton: CRC Press; 1986. p. 1–19.Google Scholar
- 53.Grinspoon L, Bakalar JB. Marihuana. The Forbidden Medicine. New Haven: Yale University Press; 1997. p. 296.Google Scholar
- 56.Ames FR, Cridland S. Anticonvulsant effect of cannabidiol. S Afr Med J. 1985;69:14.Google Scholar
- 58.Luszczki JJ, Czuczwar P, Cioczek-Czuczwar A, Czuczwar SJ. Arachidonyl- 2′-chloroethylamide, a highly selective CBs CB1 receptor agonist, enhances the anticonvulsant action of valproate in the mouse maximal electroshock- induced seizure model. Eur J Pharmacol. 2006;547:65–74.CrossRefPubMedGoogle Scholar
- 59.Monory K, Massa F, Egertová M, Eder M, Blaudzun H, Westenbroek R, Kelsch W, Jacob W, Marsch R, Ekker M, Long J, Rubenstein JL, Goebbels S, Nave KA, During M, Klugmann M, Wölfel B, Dodt HU, Zieglgänsberger W, Wotjak CT, Mackie K, Elphick MR, Marsicano G, Lutz B. The endocannabinoid system controls key epileptogenic circuits in the hippocampus. Neuron. 2006;51:455–66.CrossRefPubMedPubMedCentralGoogle Scholar
- 63.Gloss D, Vickrey B. Cannabinoids for epilepsy. Cochrane Database Syst Rev. 2014;3:CD009270.Google Scholar
- 64.Davis JP, Ramsey HH. Anti-epileptic action of marijuana active substances. Fed Proc. 1949;8:167.Google Scholar
- 67.Koppel BS, Brust JC, Fife T, Bronstein J, Youssof S, Gronseth G, Gloss D. Systematic review: efficacy and safety of medical marijuana in selected neurologic disorders: report of the Guideline Development Subcommittee of the American Academy of Neurology. Neurology. 2014;82:1556–63.CrossRefPubMedPubMedCentralGoogle Scholar
- 68.Trembly B, Sherman M. Double-blind clinical study of cannabidiol as a secondary anticonvulsant. In: Marijuana ’90 International Conference on Cannabis and Cannabinoids; 1990 July 8–11, section 2. Kolympari: International Association for CBs Medicines; 1990. p. 5.Google Scholar
- 73.Macleod J, Oakes R, Copello A, Crome I, Egger M, Hickman M, Oppenkowski T, Stokes-Lampard H, Davey Smith G. Psychological and social sequelae of cannabis and other illicit drug use by young people: a systematic review of longitudinal, general population studies. Lancet. 2004;363:1579–88.CrossRefPubMedGoogle Scholar
- 76.Friedman D, Devinsky O. Cannabinoids in the treatment of epilepsy. N Engl J Med. 2015;10(373):1048–58.Google Scholar
- 77.Devinsky O, et al. Epidiolex (Cannabidiol) in treatment resistant epilepsy, American Epilepsy Society Annual Meeting, Poster, December 7, 2015.Google Scholar
- 81.Lorenz R. Experiences with THC-treatment in children and adolescents. In: IACM 2nd Conference on CBss in Medicine. Koeln: International Association for Cannabis as Medicine; 2003. p. 6.Google Scholar